October 5, 2026
Best Real-World Data Providers for Pharma in 2026
"Neurodiscovery AI has been instrumental in transforming real-world neurology data into actionable insights that improve patient care and sustain private practice. Their commitment to neurologists—ensuring both business success and innovation in drug discovery—makes them an invaluable partner to NeuroNet and the entire field of community neurology."
Joseph V. Fritz PhDPartner,
Real-world data providers aren't a single category of vendor. Some own massive claims databases. Some specialize in a single therapeutic area. Some don't own data at all, they link other companies' datasets together. Picking among them in 2026 means knowing which of these a given study actually needs, not defaulting to the most recognizable name. This piece compares the real-world data providers pharma and biotech teams most commonly evaluate, grouped by how they actually operate, not by size alone.
What Makes a Real-World Data Provider Worth Evaluating
A few factors separate a genuinely useful RWD vendor from one that just has a large dataset:
-
Data modality. Claims data, EHR data, registry data, and genomic data each capture something different, and most providers specialize in one or two rather than all four.
-
Currency and refresh rate. A dataset that's updated quarterly behaves very differently in a feasibility study than one refreshed daily or weekly.
-
Delivery model. Some providers license data directly, some offer federated query access without the data ever leaving the source institution, and some specialize purely in linking separately-held datasets together.
-
Therapeutic-area depth. Broad providers trade depth for coverage. Specialists trade coverage for depth in one disease area, which matters more in clinically complex, heterogeneous conditions.
Category 1: Broad Longitudinal Data Providers
Optum Life Sciences
Optum Life Sciences provides one of the largest longitudinal clinical and claims datasets available to pharma, spanning commercial, HEOR, R&D, and epidemiology use cases. Frost & Sullivan named Optum Life Sciences a 2025 Leader in Real-World Evidence Solutions, and it's frequently evaluated by sponsors that need broad, cross-therapeutic coverage alongside HEOR expertise.
IQVIA
IQVIA is one of the largest real-world data providers globally, offering claims, EHR, and registry data across nearly every therapeutic area, along with clinical research and commercial analytics services. Its scale makes it a common default, though that breadth often means less clinical depth in any single disease area than a specialist provides.
Komodo Health
Komodo Health built its business around an all-payer claims dataset it calls the Healthcare Map, used primarily for patient-journey analytics and rare-disease epidemiology. Its all-payer design makes it a common choice when a study needs to find small, dispersed patient populations across the broader healthcare system.
Datavant
Datavant functions less like a traditional data owner and more like connective infrastructure, linking data across separate real-world data sources through tokenization rather than holding one unified dataset. Its 2025 acquisition of Aetion, a regulatory-grade causal-analytics platform, paired that linkage capability with methodology built specifically for FDA-facing evidence.
Category 2: Oncology-Focused Data Providers
Flatiron Health
Flatiron Health, now part of Roche, is one of the most established real-world data providers specifically in oncology, built on curated EHR data from community and academic cancer centers. It's frequently used for oncology-specific external control arms and clinical outcomes research.
ConcertAI
ConcertAI combines real-world oncology data with applied AI and clinical expertise, positioning itself as an evidence-generation partner rather than a pure data vendor. It's commonly evaluated alongside Flatiron for oncology-specific work.
Tempus
Tempus differentiates through genomic and molecular data layered onto its clinical real-world dataset, making it a frequent choice for oncology studies where molecular profiling is central to the research question.
Category 3: Indication-Specific Data Providers
Where oncology has several dedicated providers, most other therapeutic areas are still served primarily by broad, general-purpose platforms. Neurology is a clear exception.
NeuroDiscovery AI
NeuroDiscovery AI is a real-world data provider built specifically for neurology, covering 6M+ patient records and 3M+ active patients, across 1,000+ providers and 100+ clinical sites in 16+ U.S. states. Rather than treating neurology as one indication among many, the platform is built to extract the kind of clinical detail, functional scores, symptom severity, imaging findings, that general-purpose RWD providers often can't reliably pull from unstructured neurology documentation. Most sponsors pair a broad provider for cross-indication work with a specialist like this where a disease's clinical complexity demands it.
Category 4: Federated Networks and Health-System Data
TriNetX
TriNetX, majority-owned by The Carlyle Group since 2020, operates a federated global network that lets researchers query de-identified EHR, claims, and mortality data across participating healthcare organizations without the data ever leaving each institution. Its self-service interface makes it a common choice for early feasibility work across many therapeutic areas.
Truveta
Truveta is built on a consortium model, drawing data directly from participating U.S. health systems, which gives it clinical depth closer to source EHR data than most claims-based providers can offer.
Category 5: EHR-Based, Regulatory-Grade Providers
Veradigm
Veradigm provides EHR-derived real-world data intended to support regulatory-grade research, and is frequently cited alongside IQVIA and Flatiron as a source considered suitable for FDA-facing evidence generation.
How These Real-World Data Providers Compare
| Provider | Category | Data Source | Delivery Model | Best For |
|---|---|---|---|---|
| NeuroDiscovery AI | Indication-specific specialist | EHR, clinical notes | Direct license | Neurology trial design and evidence generation |
| Optum Life Sciences | Broad provider | Claims, EHR | Direct license | Cross-therapeutic depth with HEOR support |
| IQVIA | Broad provider | Claims, EHR, registries | Direct license | Enterprise-scale, multi-indication studies |
| Komodo Health | Broad provider | All-payer claims | Direct license | Rare-disease epidemiology, treatment patterns |
| Datavant (incl. Aetion) | Data linkage infrastructure | Cross-source (linked) | Tokenized linkage | FDA-facing evidence requiring data connectivity |
| Flatiron Health | Oncology specialist | Curated EHR | Direct license | Oncology external control arms |
| ConcertAI | Oncology specialist | EHR, clinical data | Direct license | Oncology evidence generation partnerships |
| Tempus | Oncology specialist | EHR, genomics | Direct license | Oncology studies needing molecular profiling |
| TriNetX | Federated network | EHR, claims, mortality | Federated query | Cross-institution feasibility and cohort building |
| Truveta | Federated network | Health-system EHR | Consortium access | Clinical-depth studies close to source EHR |
| Veradigm | EHR-based, regulatory-grade | EHR | Direct license | FDA-facing evidence generation |
Conclusion
There's no single best real-world data provider for every study, only the right fit for a specific research question. Broad providers like Optum, IQVIA, and Komodo Health offer scale and cross-indication reach. Oncology specialists like Flatiron, ConcertAI, and Tempus offer clinical and molecular depth in one disease area. Federated networks like TriNetX and Truveta offer access across institutions without centralizing the data itself. For neurology specifically, where much of the clinically meaningful detail sits in unstructured documentation that general-purpose providers often can't reliably extract, a therapeutic-area specialist like NeuroDiscovery AI tends to close a gap the broader platforms leave open.
To see how NeuroDiscovery AI's neurology-specific real-world data works, explore.
Frequently Asked Questions
- What is a real-world data provider?
- A real-world data provider supplies health information collected outside clinical trials, such as EHR, claims, or registry data, that pharma and biotech teams use for feasibility studies, HEOR, external control arms, and regulatory submissions.
- What's the difference between a broad RWD provider and a specialist?
- Broad providers cover many therapeutic areas with less clinical depth in any single one. Specialists focus on a single disease category, trading coverage for depth in the clinical detail that matters most for that condition.
- Are there real-world data providers specific to neurology?
- Most major RWD providers serve many therapeutic areas at once. NeuroDiscovery AI is built specifically for neurology, focused on extracting clinical detail from unstructured neurology documentation that general-purpose providers often miss.
- What should pharma teams look for in an RWD vendor?
- Key factors include which data modality the provider specializes in, how often the data is refreshed, whether the delivery model fits the study's needs, and whether the provider has genuine depth in the relevant therapeutic area.
- How current should real-world data be for pharma research? I
- It depends on the use case. Feasibility and site-selection work benefits from frequently refreshed data, while retrospective natural history studies can often use data on a longer refresh cycle without losing validity.
